Search - tctmd.com

Displaying 1 - 8 of 8

Sort: Relevancy | Date

News Conference News ACC 2024

Long-Awaited RCT Data Show Survival Benefit With Impella CP: DanGer Shock

Caitlin E. Cox

April 07, 2024

News Conference News ACC 2023

HALO: Baxdrostat No Better Than Placebo in Uncontrolled Hypertension

Todd Neale

March 08, 2023

News Conference News ACC 2019

Info Gleaned From FFRCT Has Durable Impact on 1-Year Outcomes: ADVANCE Registry

Caitlin E. Cox

March 18, 2019

Presentation ACC 2019

Impact of FFRCT on 1-Year Outcomes: Lessons from the ADVANCE Registry

Presenter: Manesh Patel

March 18, 2019

Cost-effectiveness of instantaneous wave-Free Ratio (iFR) compared with Fractional Flow Reserve (FFR) to guide coronary revascularization decision-making – Analysis from DEFINE FLAIR

Presentation ACC 2018

Analysis from DEFINE FLAIR Trial

Presenter: Manesh R. Patel

March 11, 2018

News Conference News ACC 2018

iFR Cheaper Than FFR Over Trajectory of 1 Year: DEFINE-FLAIR Analysis

Caitlin E. Cox

March 10, 2018

News Conference News ACC 2018

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

Shelley Wood

March 10, 2018

Video

» Interview

ACC 2022: PACIFIC AF - Multicenter, Randomized, Active Comparator-Controlled, Double-Blind, Double-Dummy, Parallel Group, Dose-Finding Phase 2 Study Comparing the Safety of the Oral FXIa Inhibitor Asundexian with Apixaban in Patients with A-Fib

April 3, 2022

Advertisement

Long-Awaited RCT Data Show Survival Benefit With Impella CP: DanGer Shock

HALO: Baxdrostat No Better Than Placebo in Uncontrolled Hypertension

Info Gleaned From FFRCT Has Durable Impact on 1-Year Outcomes: ADVANCE Registry

Impact of FFRCT on 1-Year Outcomes: Lessons from the ADVANCE Registry

Analysis from DEFINE FLAIR Trial

iFR Cheaper Than FFR Over Trajectory of 1 Year: DEFINE-FLAIR Analysis

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

ACC 2022: PACIFIC AF - Multicenter, Randomized, Active Comparator-Controlled, Double-Blind, Double-Dummy, Parallel Group, Dose-Finding Phase 2 Study Comparing the Safety of the Oral FXIa Inhibitor Asundexian with Apixaban in Patients with A-Fib

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content